Literature DB >> 23260503

Endocarditis and risk of cancer: a Danish nationwide cohort study.

Reimar Wernich Thomsen1, Dóra Körmendiné Farkas, Søren Friis, Claus Sværke, Anne Gulbech Ording, Mette Nørgaard, Henrik Toft Sørensen.   

Abstract

BACKGROUND: Endocarditis may be a marker for bacteremia-associated occult cancer. Intensive antibiotic treatment in endocarditis is suggested to reduce long-term cancer risk. We examined these hypotheses in a nationwide cohort study.
METHODS: Endocarditis patients and cancer cases were identified from the Danish National Registry of Patients and the Danish Cancer Registry during 1978-2008. We compared the incidences of various cancers among study subjects to expected incidences based on national age-, sex-, and site-specific rates.
RESULTS: We observed 997 cancers among 8445 endocarditis patients (median follow-up of 3.5 years), reflecting an increased standardized incidence rate (SIR) of 1.61 (95% confidence interval [CI], 1.51-1.71). Cancer risk was highly elevated during the first 3 months of follow-up (SIR=8.03; 95% CI, 6.92-9.26), partly due to a 15- to 30-fold increased risk of hematological or liver cancers. Between 3-month and 5-year follow-ups, cancer incidence remained 1.5-fold higher than expected, including 2- and 4-fold increased SIRs for colorectal and liver cancers, respectively. Beyond 5 years of observation, the overall cancer SIR was 1.21 (95% CI, 1.10-1.34). Long-term associations were weak for several cancers hypothesized to be associated with antibiotic use, including prostate, gastric, and breast cancer.
CONCLUSION: Endocarditis is a substantial clinical marker for presence of occult cancer. We found no evidence of decreased long-term cancer risk after antibiotic treatment for endocarditis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23260503     DOI: 10.1016/j.amjmed.2012.07.026

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy?

Authors:  Salvatore Patanè
Journal:  J Cardiovasc Transl Res       Date:  2014-02-25       Impact factor: 4.132

Review 2.  Infective Endocarditis in the Elderly: Challenges and Strategies.

Authors:  Carlos Bea; Sara Vela; Sergio García-Blas; Jose-Angel Perez-Rivera; Pablo Díez-Villanueva; Ana Isabel de Gracia; Eladio Fuertes; Maria Rosa Oltra; Ana Ferrer; Andreu Belmonte; Enrique Santas; Mauricio Pellicer; Javier Colomina; Alberto Doménech; Vicente Bodi; Maria José Forner; Francisco Javier Chorro; Clara Bonanad
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-17

Review 3.  Malignancy and Endocarditis: Divulging Into the Intertwined Association.

Authors:  Lakshmi Sree Pugalenthi; Mahlika Ahmad; Sanjana Reddy; Zineb Barkhane; Jalal Elmadi; Lakshmi Satish Kumar
Journal:  Cureus       Date:  2022-04-12

Review 4.  The impact of comorbidity on cancer survival: a review.

Authors:  Mette Søgaard; Reimar Wernich Thomsen; Kristine Skovgaard Bossen; Henrik Toft Sørensen; Mette Nørgaard
Journal:  Clin Epidemiol       Date:  2013-11-01       Impact factor: 4.790

5.  Infective Endocarditis and Cancer Risk: A Population-Based Cohort Study.

Authors:  Li-Min Sun; Jung-Nan Wu; Cheng-Li Lin; Jen-Der Day; Ji-An Liang; Li-Ren Liou; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 6.  Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.

Authors:  Lisa M Tilemann; Markus B Heckmann; Hugo A Katus; Lorenz H Lehmann; Oliver J Müller
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

7.  Increased risk of incident primary cancer after Staphylococcus aureus bacteremia: A matched cohort study.

Authors:  Nanja Gotland; M L Uhre; H Sandholdt; N Mejer; L F Lundbo; A Petersen; A R Larsen; T Benfield
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.